RecruitingNCT06838143

Ilaris NIS in Korea

Real Life Non-interventional Study on Safety and Effectiveness of Ilaris® (Canakinumab) 150 mg for Subcutaneous Injection in Hereditary Periodic Fever Syndrome (CAPS, crFMF, TRAPS and HIDS/MKD) Patients and sJIA Patients (REASSURE)

Sponsor

Novartis Pharmaceuticals

Enrollment

25 participants

Start Date

Mar 29, 2025

Study Type

OBSERVATIONAL

Conditions

Systemic Juvenile Idiopathic Arthritis (sJIA)Hereditary Periodic Fever Syndromes Cryopyrin-associated Periodic Syndromes (CAPS)Colchicine Resistance Familial Mediterranean Fever (crFMF)TNF Receptor Associated Periodic Syndrome (TRAPS)Hyper-IgD Syndrome / Mevalonate Kinase Deficiency (HIDS/MKD)

Summary

This is a study to evaluate safety and effectiveness of Ilaris in adult and pediatric patients receiving the drug in a clinical setting for any of the following indications, Hereditary Periodic Fever Syndromes, Cryopyrin-associated periodic syndromes (CAPS), colchicine resistance familial Mediterranean fever (crFMF), TNF receptor associated periodic syndrome (TRAPS), Hyper-IgD syndrome / Mevalonate kinase deficiency (HIDS/MKD) or Systemic juvenile idiopathic arthritis (sJIA).

Eligibility

Min Age: 2 YearsMax Age: 100 Years

Plain Language Summary

Simplified for easier understanding

This clinical trial is studying a biological treatment called Ilaris for people with colchicine resistance familial mediterranean fever (crfmf), cryopyrin-associated periodic syndromes (caps), and other related conditions. The study is currently recruiting participants at 1 location. People eligible for this study include aged 2 Years to 100 Years.

This summary was AI-generated to explain the trial in plain language. It is not medical advice. Always discuss eligibility with your doctor before enrolling in a clinical trial.

Interested in this trial?

Get notified about updates and connect with the research team.